TipRanks
DuPont de Nemours (IT:1DD)
:1DD
Italy Market
EarningsQ2 2026 Earnings Report

DuPont de Nemours (1DD) Q2 2026 Earnings Report

3 Followers

IT:1DD Q2 2026 EPS Results

Actual EPS€1.68
Consensus EPS€1.57
Beat/MissBeat by +€0.11
One Year Ago EPS€1.25

IT:1DD Q2 2026 Revenue Results

Actual Revenue€1.62B
Expected Revenue€1.61B
Beat/MissBeat by +€11.18M
YoY Revenue Growth-44.15%

Earnings Announcement Details

QuarterQ2 2026
Date08/04/2026
TimeBefore Open
Conference CallTuesday, August 4, 2026
IT:1DD Upcoming Earnings
DuPont de Nemours's next earnings date is estimated for November 3, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

IT:1DD Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 04, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call was broadly positive: DuPont reported a quarter that beat guidance across key metrics (sales, EBITDA, EPS), delivered strong free cash flow (127% conversion), raised full-year guidance, announced a $250M buyback and showcased operational improvements (productivity, OTIF, lower cost of poor quality) and promising commercial/innovation momentum (AI-enabled sales plays, DLE launch, EV battery ramp). Offsetting items include near-term timing and project headwinds in the Middle East impacting Water, margin pressure in Healthcare & Water from mix and investments, oil & gas inflationary headwinds (partially mitigated by $90M of pricing), and modest currency headwinds. Overall the positives — improved organic growth, margin expansion, cash generation, capital allocation actions, and scaling commercial and operational programs — outweigh the localized and addressable headwinds.
Company Guidance
DuPont raised full‑year 2026 guidance after a strong Q2 beat (Q2 net sales $1.8B, +4% organic; operating EBITDA $448M, +8%; EBITDA margin 24.6%, +80 bps; adj. EPS $1.88, +21%; transaction‑adjusted FCF $326M, 127% conversion). The company now expects full‑year net sales midpoint $7.175B with organic growth slightly ahead of 4%, operating EBITDA midpoint $1.760B and operating EBITDA margin ~24.5% (including a ~30 bps oil & gas inflation headwind), adj. EPS midpoint $7.24 (≈+18% vs PY pro forma), and free cash flow conversion expected ahead of the 90% target (closer to 100%). For H2 the company estimates net sales $3.675B with ~6% organic growth, operating EBITDA $900M (margin ~24.5% including a ~50 bps oil & gas headwind) and H2 adj. EPS midpoint $3.73; Q3 guidance is net sales $1.835B, operating EBITDA $448M, margin ~24.4% (50 bps headwind), adj. EPS $1.80–$1.90, and ~5% organic growth (adjusted for prior‑year timing), while capital allocation includes a $250M share repurchase announced for Q3.
Beat Guidance and Raised Full-Year Outlook
Q2 performance exceeded prior guidance and management raised full-year 2026 targets: organic sales growth now expected slightly ahead of 4%, operating EBITDA midpoint increased to $1.760 billion, and adjusted EPS midpoint raised to $7.24 (approximately +18% vs prior year pro forma and +$0.15 vs prior guide).
Strong Quarterly Financial Results
Net sales of $1.8 billion (up 4% year-over-year on 4% organic growth); operating EBITDA of $448 million (up 8% YoY) and operating EBITDA margin of 24.6% (up 80 basis points YoY); adjusted EPS of $1.88 (up 21% YoY).
Robust Cash Flow and Capital Deployment
Transaction-adjusted free cash flow of $326 million with conversion of 127%; management expects full-year free cash flow conversion to be ahead of the 90% target and CFO said closer to 100% on a full-year basis. Announced a $250 million share repurchase program launching in Q3 and retained >$1 billion of capacity for M&A.
Operational Productivity and Quality Gains
Delivered ~200 basis points COGS reduction this quarter (contributing ~100 basis points of margin expansion); set a net productivity target of 3% of COGS (goal within ~18 months); OTIF and net productivity improved by more than 100 basis points; cost of poor quality ~4% of sales (below ~5% benchmark).
Innovation Pipeline and Commercial Execution
Innovation vitality index ~35%; launched AI-enabled commercial initiatives with ~50 sales plays and ~150 opportunities (nearly 30% win rate in targeted garment plays), shortening sales-play deployment to ~4 weeks and generating ~$5–6 million incremental garment sales.
Diversified Industrials Momentum
Diversified Industrials net sales $963 million (up 3% YoY organic); operating EBITDA $213 million (up 7% YoY) and margin expanded to 22.1% (up 70 basis points YoY). Building Technologies and Industrial Technologies showed growth, with aerospace and EV battery applications driving mid-single-digit gains in Industrial Technologies.
Healthcare & Water Growth and New Solutions
Healthcare & Water net sales $856 million (up 5% YoY — 4% organic + 1% currency). Healthcare delivered mid-single-digit organic growth, driven by personal protection and biopharma; launched integrated DLE (direct lithium extraction) solution and expanded the Liveo biopharma portfolio.
Battery & Semiconductor Opportunity Capture
EV battery-related revenue ~ $70 million today with management expecting it to reach triple digits in 2026–2027; broader EV opportunity is a few hundred million. Water ultra-pure solutions for semiconductor customers have been growing strongly (>20%+ in recent quarters).

IT:1DD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Nov 03, 2026
2026 (Q3)
1.67 / -
2.918―
2026 (Q2)
1.57 / 1.68
1.25433.81% (+0.42)
2026 (Q1)
1.31 / 1.47
1.15327.71% (+0.32)
2025 (Q4)
1.15 / 1.23
1.266-2.68% (-0.03)
2025 (Q3)
1.25 / 2.92
1.322120.80% (+1.60)
2025 (Q2)
1.19 / 1.25
1.08615.45% (+0.17)
2025 (Q1)
1.07 / 1.15
0.88430.37% (+0.27)
2024 (Q4)
1.10 / 1.27
0.97529.85% (+0.29)
2024 (Q3)
1.15 / 1.32
1.0328.34% (+0.29)
2024 (Q2)
0.95 / 1.09
0.95214.06% (+0.13)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed